| 前收市價 | 55.28 |
| 開市 | 無 |
| 買盤 | 43.50 |
| 賣出價 | 47.50 |
| 拍板 | 85.00 |
| 到期日 | 2024-11-15 |
| 今日波幅 | 55.28 - 55.28 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 48 |
Investor's Business DailySarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Sarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.
Barrons.comPfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
The drug company said a gene therapy it is testing failed to improve motor function in boys aged 4 to 7.
InvestorPlaceExit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
If a portfolio is passively managed, investors tend to buy and forget. This however holds true for high-quality blue-chip and growth stocks. On the other hand, in an actively managed portfolio, there will be ample opportunity for a good entry or exit. The times of extreme euphoria are the best for selling, and buying on panic gives the stock ample headroom to rally. The focus of this column is on overvalued stocks to sell before they correct sharply. An important point to note is that the overva
